Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ALNY - Alnylam Pharmaceuticals, Inc.
Market Cap 23.29B P/E - EPS this Y 29.30% Ern Qtrly Grth -
Income -72.94M Forward P/E -81.66 EPS next Y 43.80% 50D Avg Chg -4.00%
Sales 2.34B PEG 0.62 EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book N/A EPS next 5Y -177.50% 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 2.78 Shares Outstanding 128.38M 52W Low Chg 4.00%
Insider Own 0.42% ROA 1.73% Shares Float 127.84M Beta 0.38
Inst Own 95.62% ROE - Shares Shorted/Prior 4.45M/4.52M Price 187.01
Gross Margin 87.00% Profit Margin -3.11% Avg. Volume 556,961 Target Price 289.58
Oper. Margin 7.37% Earnings Date Oct 31 Volume 618,142 Change -1.08%
Healthcare | Biotechnology | United States
About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc. News
12/20/24 The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
12/19/24 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
12/11/24 CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
12/04/24 What Makes Alnylam (ALNY) a New Buy Stock
12/04/24 Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?
12/02/24 Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now?
11/27/24 Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
11/27/24 Kronos, Idorsia plan layoffs; PTC shelves ALS drug
11/26/24 FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
11/25/24 BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
11/25/24 Exploring Three High Growth Tech Stocks In The United States
11/25/24 Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
02:16 PM BridgeBio heart drug approved by FDA, setting up battle with Pfizer
11/18/24 ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
11/18/24 Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
11/17/24 Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
11/12/24 3 US Stocks Estimated To Be Trading At Discounts Up To 48.8%
11/06/24 Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
11/06/24 An RNAi renaissance is creating a new generation of startups
11/04/24 Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Garg Pushkal CMO & EVP Dev & Med.. CMO & EVP Dev & Med Affairs Aug 03 Sell 186.14 7,627 1,419,690 4,345 08/07/23
Poulton Jeffrey V. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 03 Sell 186.95 3,460 646,847 15,873 08/07/23
Greenstreet Yvonne Chief Executive Offi.. Chief Executive Officer Aug 03 Sell 186.95 4,057 758,456 35,216 08/07/23
Vaishnaw Akshay President President Aug 03 Sell 186.95 4,057 758,456 22,774 08/07/23
Greenstreet Yvonne Chief Executive Offi.. Chief Executive Officer Apr 26 Sell 194.96 7,615 1,484,620 30,332 04/28/23
Poulton Jeffrey V. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 26 Sell 194.96 977 190,476 11,706 04/28/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 26 Sell 194.96 1,476 287,761 1,801 04/28/23
Vaishnaw Akshay President President Apr 26 Sell 194.96 2,392 466,344 17,890 04/28/23
Garg Pushkal CMO & EVP Dev & Med.. CMO & EVP Dev & Med Affairs Apr 26 Sell 196.92 4,294 845,574 4,345 04/28/23
Franchini Indrani Lall EVP, CLO & Secretary EVP, CLO & Secretary Feb 01 Sell 225.94 1,675 378,450 3,500 02/03/23
Franchini Indrani Lall EVP, CLO & Secretary EVP, CLO & Secretary Feb 01 Option 0 5,175 5,175 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 01 Sell 228.76 5,025 1,149,519 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 01 Option 0 5,025 5,025 02/03/23
Tanguler Tolga EVP, Chief Commercia.. EVP, Chief Commercial Officer Jul 05 Sell 150.0 1,754 263,100 1,754 07/07/22
Vaishnaw Akshay President, R&D President, R&D Dec 21 Sell 190.24 2,879 547,701 11,215 12/23/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 12 Sell 172.3 33,978 5,854,409 214,765 11/12/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 12 Option 7.1 33,978 241,244 248,743 11/12/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer May 17 Option 7.1 33,979 241,251 248,744 05/17/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer May 17 Sell 131.34 33,979 4,462,802 214,765 05/17/21
Vaishnaw Akshay President, R&D President, R&D Apr 21 Sell 137.67 6,438 886,319 14,119 04/21/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Feb 26 Option 7.1 33,979 241,251 240,015 02/26/21
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Feb 26 Sell 149.18 33,979 5,068,987 206,036 02/26/21
KEATING LAURIE EVP, Chief Legal Off.. EVP, Chief Legal Officer Jan 15 Option 81.2 9,027 732,992 11,261 01/15/21
KEATING LAURIE EVP, Chief Legal Off.. EVP, Chief Legal Officer Jan 15 Sell 171 9,027 1,543,617 2,234 01/15/21
PAUL STEVEN M Director Director Dec 22 Option 9.3 15,000 139,500 16,000 12/22/20
PAUL STEVEN M Director Director Dec 22 Sell 140 15,000 2,100,000 1,000 12/22/20
SHARP PHILLIP A Director Director Nov 30 Option 9.3 30,000 279,000 265,633 11/30/20
SHARP PHILLIP A Director Director Nov 30 Sell 125.74 30,000 3,772,200 235,633 11/30/20
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 20 Option 9.14 34,765 317,752 232,354 11/20/20
MARAGANORE JOHN Chief Executive Offi.. Chief Executive Officer Nov 20 Sell 125 34,765 4,345,625 197,589 11/20/20
Vaishnaw Akshay President, R&D President, R&D Oct 01 Option 42.22 971 40,996 15,090 10/01/20
Vaishnaw Akshay President, R&D President, R&D Oct 01 Sell 140 971 135,940 14,119 10/01/20